To include your compound in the COVID-19 Resource Center, submit it here.

Sucampo ending cobiprostone development

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) said it will discontinue development

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE